Ophthalmic Drugs Market Forecast 2014-2024
Prospects for Leading Companies

世界の眼科医薬品市場予測:網膜疾患/アレルギー性炎症/緑内障/眼球乾燥症治療薬

◆タイトル:Ophthalmic Drugs Market Forecast 2014-2024
Prospects for Leading Companies
◆商品コード:VISG409051
◆調査・発行会社:visiongain
◆発行日:2014年6月
◆ページ数:337
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single user licence(1名使用)GBP1,799 ⇒換算¥278,845見積依頼/購入/質問フォーム
Dept Licence(部署内共有可)GBP2,999 ⇒換算¥464,845見積依頼/購入/質問フォーム
Site Licence(同一国内社内共有可)GBP4,999 ⇒換算¥774,845見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

本調査レポートでは、"世界の眼科医薬品市場予測:網膜疾患/アレルギー性炎症/緑内障/眼球乾燥症治療薬"について調査・分析し、レポートサマリー、市場動向、世界市場規模・市場予測、地域別市場分析、主要国別市場分析、市場環境分析、研究開発パイプライン分析、専門家の見解、主要企業分析、結論などの情報をお届けいたします。

Ophthalmic drugs – new study showing you trends, R&D progress, and predicted revenues
Where is the ophthalmic drugs market heading? Visiongain’s brand new report shows you potential revenues to 2024, assessing data, trends, opportunities and prospects there.

Our 337-page report provides 198 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and national level. You will see financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in this growing pharma market.

Forecasts from 2014-2024 and other analyses show you commercial prospects
Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and Porter’s Five Forces Analysis), company profiles and commercial developments. Read the full transcripts of ten exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales, including:
• Cathy Yelf, Head of External Relations, Macular Society
• RNIB (Royal National Institute of Blind People)
• Charles C Wykoff, Dr, Retina Consultants of Houston
• Manju Subramanian, Associate Professor, Boston University School of Medicine
• Vanda Pharmaceuticals
• Professor David T. Shima, PhD, Institute of Ophthalmology, University College London
• Anonymous interview
• Sean Ainsworth, CEO and Founder of RetroSense Therapeutics
• Philip G. Ralston, Jr., CEO of MacuCLEAR
• Dr Michael Stewart, Associate Professor, Mayo Clinic

Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, you see forecasts to 2024 for these five submarkets:
• Retinal disorders
• Allergic, inflammatory and infective drugs
• Glaucoma
• Dry eye
• Other treatments.

Our investigation discusses what stimulates and restrains business. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.

See revenue forecasts for products
How will leading drugs perform to 2024 at world level? Our study forecasts sales of 26 products, including these brands:
• Lucentis
• Eylea
• Restasis
• Lumigan and Ganfort
• Xalatan/Xalacom
• Travatan/Travatan Z and DuoTrav
• Alphagan/Alphagan P and Combigan
• Refresh brand products
• Pataday
• Vigamox

Discover how high revenues can go. You see what’s happening, understanding trends, challenges and opportunities.

Our analysis also breaks the main world forecast into geographical markets.

What are the prospects in the leading regions and countries?
In addition to analyses of the overall world market, you discover individual revenue forecasts for 12 leading national markets to 2024:
• US
• Japan
• China
• Germany
• France
• UK
• Italy
• Spain
• India
• Brazil
• Russia
• Mexico
• Rest of the World

There will be growth in established pharma markets and in developing countries. Our analyses show that India, China, Mexico and Brazil, in particular, will continue to achieve high revenue growth to 2024. Developments worldwide in product approval and pricing will influence the market.

Leading companies and potential for market growth
Overall world revenue for ophthalmic drugs will reach $20.9bn in 2014, our work forecasts. We predict steady revenue growth from 2014 to 2024. Rising demand for ophthalmic drugs, expanding healthcare coverage, the strength of the R&D pipeline and developments in drug delivery technologies will increase sales to 2024.

Our work shows you what organisations hold greatest potential. See profiles of 10 leading companies, including these:
• Novartis (Alcon)
• Allergan
• Roche
• Valeant (including Bausch & Lomb)
• Regeneron
• Santen
• Pfizer
• Merck & Co.
• Bayer
• Senju

A company profile gives you the following information:
• Revenue forecast for ophthalmic drugs from 2014 to 2024
• Discussion of a company’s activities and outlook
• Recent financial results
• Assessment of recent developments – mergers and acquisitions (M&A), new products, and collaborations, including alliances, partnerships and joint ventures

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

【レポートの目次】

1. Report Overview
1.1 Global Ophthalmic Drugs Market Overview
1.2 Global Ophthalmic Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2. Introduction to Ophthalmic Drugs
2.1 The Pharmaceutical Industry: a Very Brief Overview
2.2 The Eye: An Overview of Its Structure and Function
2.3 The Global Burden of Eye Disease
2.4 Ophthalmic Drugs: Market Segmentation
2.5 Glaucoma: the ‘Silent Thief of Sight’
2.5.1 A Classification of Glaucoma
2.5.1.1 Primary Open-Angle Glaucoma
2.5.1.2 Acute Angle-Closure Glaucoma
2.5.1.3 Congenital Glaucoma
2.5.1.4 Secondary Glaucoma
2.5.1.5 Normal-Tension Glaucoma
2.5.1.6 Ocular Hypertension
2.5.2 Risk Factors for Glaucoma
2.5.3 Diagnosis of Glaucoma
2.5.4 Drug Treatment of Glaucoma
2.5.5 Laser Treatment and Surgery for Glaucoma
2.6 Age-Related Macular Degeneration (AMD)
2.6.1 Dry (non-exudative) AMD
2.6.2 Wet (exudative) AMD
2.6.3 Risk Factors for AMD
2.6.4 Diagnosis of AMD
2.6.5 Treatment of AMD
2.7 Diabetic Retinopathy (DR)
2.7.1 Diagnosis of Diabetic Retinopathy
2.7.2 Treatment of Diabetic Retinopathy
2.8 Ocular Allergy and Allergic Conjunctivitis
2.8.1 Diagnosis of Ocular Allergy
2.8.2 Treatment of Ocular Allergy
2.9 Ocular Inflammatory Disease
2.9.1 Treatment of Ocular Inflammatory Disease
2.10 Eye Infections
2.10.1 Treatment of Eye Infections
2.11 Dry Eye Syndrome
2.11.1 Treatment of Dry Eye Syndrome
2.12 Phases of Clinical Trials
2.13 Scope of this Report
2.14 Currency Exchange Rates in This Report

3. Ophthalmic Drugs: World Market 2014-2024
3.1 The World Ophthalmic Drugs Market in 2013
3.1.1 Leading Ophthalmic Drugs
3.1.2 Leading Companies in the Ophthalmic Drugs Market
3.2 World Ophthalmic Drugs Market: Sales Forecast 2014-2024
3.3 Retinal Disorder Drugs Lead the World Ophthalmic Drugs Market
3.4 How Will Segmental Market Shares Change to 2024?
3.4.1 World Ophthalmic Drugs Market: Drivers and Restraints 2014-2024

4. Leading National Markets 2014-2024
4.1 Geographical Breakdown of the World Ophthalmic Drugs Market
4.2 World Ophthalmic Drugs Market: National Markets Forecast 2014-2024
4.2.1 How Will National Market Shares Change to 2024?
4.3 The US Ophthalmic Drugs Market 2014-2024
4.3.1 US Ophthalmic Drugs Market Forecast 2014-2024
4.3.2 US Ophthalmic Drugs Market: Trends and Developments
4.3.2.1 Affordable Care Act: Expanding Medicare Coverage
4.3.2.2 A US Biosimilars Market?
4.4 Japanese Ophthalmic Drugs Market 2014-2024
4.4.1 Japanese Ophthalmic Drugs Market Forecast 2014-2024
4.4.2 Japanese Ophthalmic Drugs Market: Trends and Developments
4.4.2.1 The Cost of Treatment in Japan
4.5 Chinese Ophthalmic Drugs Market 2014-2024
4.5.1 Chinese Ophthalmic Drugs Market Forecast 2014-2024
4.5.2 Chinese Ophthalmic Drugs Market: Trends and Developments
4.5.2.1 Expansion of Healthcare Coverage and Reimbursement
4.5.2.2 Price Controls and the Anhui Model
4.6 EU5 Ophthalmic Drugs Market 2014-2024
4.6.1 German Ophthalmic Drugs Market Forecast 2014-2024
4.6.2 French Ophthalmic Drugs Market Forecast 2014-2024
4.6.3 UK Ophthalmic Drugs Market Forecast 2014-2024
4.6.4 Italian Ophthalmic Drugs Market Forecast 2014-2024
4.6.5 Spanish Ophthalmic Drugs Market Forecast 2014-2024
4.7 Brazilian Ophthalmic Drugs Market 2014-2024
4.7.1 Brazilian Ophthalmic Drugs Market Forecast 2014-2024
4.7.2 Brazilian Ophthalmic Drugs Market: Trends and Developments
4.7.2.1 Increasing Access to Medicines
4.8 Russian Ophthalmic Drugs Market 2014-2024
4.8.1 Russian Ophthalmic Drugs Market Forecast 2014-2024
4.8.2 Russian Ophthalmic Drugs Market: Trends and Developments
4.8.2.1 Pharma2020, Healthcare and Industry Reform
4.9 Indian Ophthalmic Drugs Market 2014-2024
4.9.1 Indian Ophthalmic Drugs Market Forecast 2014-2024
4.9.2 Indian Ophthalmic Drugs Market: Trends and Developments
4.9.2.1 Drug Prices Control Order 2013
4.9.2.2 Expansion of Healthcare Provision
4.10 Mexican Ophthalmic Drugs Market 2014-2024
4.10.1 Mexican Ophthalmic Drugs Market Forecast 2014-2024
4.10.2 Mexican Ophthalmic Drugs Market: Trends and Developments
4.10.2.1 Lupin Acquires Laboratorios Grin, Entering the Mexican Market
4.10.2.2 Seguro Popular: Mexican Healthcare Reform
4.10.2.3 International Interest in Mexico

5. Retinal Disorder Drugs Market 2014-2024
5.1 Retinal Disorder Drugs: the Rise of Anti-VEGF Therapy
5.2 Leading Retinal Disorder Drugs in 2013
5.3 Retinal Disorder Drugs: Market Forecast 2014-2024
5.4 Market Share of Leading Retinal Disorder Drugs to 2024
5.5 Retinal Disorder Drugs: Trends and Developments
5.5.1 Lucentis Dominates the Retinal Disorder Drugs Market
5.5.2 Roche and Novartis Fined Over Lucentis-Avastin Collusion
5.5.3 Requiring Avastin Use in AMD?
5.5.4 Novartis Licenses Ophthotech’s Fovista
5.5.5 Jetrea Launch Disappoints Analysts
5.5.6 Conbercept Approved in China
5.5.7 Drug/Device Combination Products Entering the Market
5.5.8 Advances in Regenerative Medicine
5.6 Lucentis (ranibizumab, Roche/Novartis)
5.6.1 Lucentis: Sales Forecast 2014-2024
5.6.2 Less Frequent Dosing Approved in US
5.6.3 New Indications for Lucentis
5.6.4 Lucentis/Fovista Combination Therapy?
5.7 Eylea (aflibercept, Regeneron/Bayer/Santen)
5.7.1 Eylea: Sales Forecast 2014-2024
5.7.2 The Comparative Efficacy of Eylea
5.7.3 Combination Therapy with Eylea and a PDGFR-beta Inhibitor
5.8 Avastin (bevacizumab, Roche)
5.8.1 Avastin: Sales Forecast 2014-2024
5.8.2 Compounding Pharmacies and Safety Risks
5.9 Visudyne (verteporfin, Valeant/Novartis)
5.9.1 Visudyne: Sales Forecast 2014-2024
5.10 Jetrea (ocriplasmin, ThromboGenics/Novartis)
5.10.1 Jetrea: Sales Forecast 2014-2024
5.10.2 Potential Acquisition of ThromboGenics?
5.10.3 R&D Agreements with Eleven Biotherapeutics and Bicycle Therapeutics
5.11 Other Retinal Disorder Drugs
5.11.1 Iluvien (fluocinolone implant, Alimera Sciences)
5.11.2 Ozurdex (dexamethasone implant, Allergan)

6. Allergic, Inflammatory and Infective Drugs Market 2014-2024
6.1 Allergic, Inflammatory and Infective Drugs: Introduction
6.2 Allergic, Inflammatory and Infective Drugs: Submarket Breakdown
6.3 Leading Allergic, Inflammatory and Infective Drugs in 2013
6.4 Allergic, Inflammatory and Infective Drugs: Market Forecast 2014-2024
6.5 Market Share of Leading Allergic, Inflammatory and Infective Drugs to 2024
6.6 Allergic, Inflammatory and Infective Drugs: Trends and Developments
6.6.1 Growth Prospects in 2014-2024
6.6.2Lupin Launches Generic Zymaxid
6.6.3 New Topical NSAIDs Launched: Prolensa and Ilevro
6.7 Patanol and Pataday (olopatadine, Alcon)
6.7.1 Patanol: Sales Forecast 2014-2024
6.7.2 Pataday: Sales Forecast 2014-2024
6.7.3 Generic Competition for Patanol/Pataday?
6.8 Vigamox (moxifloxacin, Alcon)
6.8.1 Vigamox: Sales Forecast 2014-2024
6.8.2 Generic Challenges to Vigamox
6.8.3 Moxeza: A Next-Generation Form of Vigamox
6.9 TobraDex (tobramycin/dexamethasone, Alcon)
6.9.1 TobraDex: Sales Forecast 2014-2024
6.9.2 TobraDex ST (Alcon/Novartis)
6.10 Bromday (bromfenac, Valeant)
6.10.1 Bromday: Sales Forecast 2014-2024
6.10.2 Prolensa: A New Formulation of Bromfenac
6.10.3 Competition from Ilevro/Nevanac
6.11 Cravit (levofloxacin, Santen)
6.11.1 Cravit: Sales Forecast 2014-2024
6.12 Acular (ketorolac, Allergan)
6.12.1 Acular: Sales Forecast 2014-2024
6.13 AzaSite (azithromycin, Akorn)
6.13.1 AzaSite: Sales Forecast 2014-2024

7. Glaucoma Drugs Market 2014-2024
7.1 Glaucoma: Prostaglandin Analogues Lead the Market
7.2 Leading Glaucoma Drugs in 2013
7.3 Glaucoma Drugs: Market Forecast 2014-2024
7.4 Market Share of Leading Glaucoma Drugs to 2024
7.5 Glaucoma Drugs: Trends and Developments
7.5.1 Revenues Threatened by Patent Expiration
7.5.2 Preservative-Free Formulation Trends
7.5.3 Innovation in Treatments for Glaucoma
7.5.4 Simbrinza Launched as First Beta-Blocker-Free Combination
7.6 Lumigan and Ganfort (bimatoprost, Allergan)
7.6.1 Lumigan and Ganfort: Sales Forecast 2014-2024
7.7 Xalatan and Xalacom (latanoprost, Pfizer)
7.7.1 Xalatan/Xalacom: Sales Forecast 2014-2024
7.8 Travatan/Travatan Z and DuoTrav (travoprost, Novartis)
7.8.1 Travatan/Travatan Z and DuoTrav: Sales Forecast 2014-2024
7.9 Alphagan/Alphagan P and Combigan (brimonidine, Allergan)
7.9.1 Alphagan/Alphagan P and Combigan: Sales Forecast 2014-2024
7.10 Trusopt and Cosopt/Cosopt PF (dorzolamide, Merck)
7.10.1 Trusopt: Sales Forecast 2014-2024
7.10.2 Cosopt and Cosopt PF: Sales Forecast 2014-2024
7.11 Azopt (brinzolamide, Novartis)
7.11.1 Azopt: Sales Forecast 2014-2024
7.12 Tapros (tafluprost, Santen)
7.12.1 Tapros/Taflotan: Sales Forecast 2014-2024
7.13 Zioptan (tafluprost, Akorn)
7.13.1 Zioptan: Sales Forecast 2014-2024

8. Dry Eye Drugs Market 2014-2024
8.1 Dry Eye: Introduction
8.2 Leading Dry Eye Drugs in 2013
8.3 Dry Eye Drugs: Market Forecast 2014-2024
8.4 Market Share of Leading Dry Eye Drugs to 2024
8.5 Dry Eye Drugs: Trends and Developments
8.5.1 Will Generic Restasis Launch in 2014?
8.5.2 Intensive Research Focus on Dry Eye
8.5.3 Improving Diagnostic Tools
8.6 Restasis (ciclosporin, Allergan)
8.6.1 Restasis: Sales Forecast 2014-2024
8.7 Refresh Brand Products (Allergan)
8.7.1 Refresh Brand Products: Sales Forecast 2014-2024
8.8 Hyalein (hyaluronic acid, Santen)
8.8.1 Hyalein: Sales Forecast 2014-2024
8.9 Diquas (diaquafosol, Santen)
8.9.1 Diquas: Sales Forecast 2014-2024
8.10 Other Ophthalmic Drugs
8.10.1 Hetlioz (tasimelteon, Vanda Pharmaceuticals)
8.10.2 Hetlioz: Sales Forecast 2014-2024

9. Leading Companies in the Ophthalmic Drugs Market
9.1 Novartis (Alcon)
9.1.1 Novartis: Ophthalmic Drugs Portfolio
9.1.2 Novartis: Sales Forecast 2014-2024
9.1.3 Novartis: Products in Development
9.1.4 Novartis: Recent Developments
9.1.4.1 Novartis Restructures Following Strategic Review
9.1.4.2 Novartis Licenses Ophthothech’s Fovista
9.2 Allergan
9.2.1 Allergan: Ophthalmic Drugs Portfolio
9.2.2 Allergan: Sales Forecast 2014-2024
9.2.3 Allergan: Products in Development
9.2.3.1 Novadur (Intravitreal Brimonidine Implant)
9.2.4 Allergan: Recent Developments
9.2.4.1 Ozurdex (Dexamethasone Intravitreal Implant): The First Drug Therapy for Diabetic Macular Oedema
9.2.4.2 Prospects for Generic Restasis?
9.2.4.3 Allergan Rejects Valeant Bid
9.2.4.4 Allergan Considering Acquiring Shire?
9.3 Roche
9.3.1 Roche: Ophthalmic Drugs Portfolio
9.3.1.1 Lucentis: US Sales Forecast 2014-2024
9.3.2 Roche: Sales Forecast 2014-2024
9.3.3 Roche: Products in Development
9.4 Valeant
9.4.1 Valeant: Ophthalmic Drugs Portfolio
9.4.2 Valeant: Sales Forecast 2014-2024
9.4.3 Valeant: Products in Development
9.4.4 Valeant: Recent Developments
9.4.4.1 Valeant’s Acquisition of Bausch and Lomb: Aggressive Expansion?
9.4.4.2 Bausch and Lomb Had Acquired ISTA Pharmaceuticals
9.5 Regeneron
9.5.1 Regeneron: Ophthalmic Drugs Portfolio
9.5.2 Regeneron: Sales Forecast 2014-2024

9.5.3 Regeneron: Products in Development
9.5.4 Regeneron: Recent Developments
9.5.4.1 FDA Approves Zaltrap (aflibercept)
9.5.4.2 Eylea/Zaltrap and the Davis-Smyth Patent Agreements
9.6 Santen
9.6.1 Santen: Ophthalmic Drugs Portfolio
9.6.2 Santen: Sales Forecast 2014-2024
9.6.3 Santen: Products in Development
9.6.4 Santen: Recent Developments
9.6.4.1 Santen Acquires Novagali Pharma
9.6.4.2 Santen Launches Alesion in Japan
9.6.4.3 Santen Acquires Merck’s Ophthalmic Drugs Portfolio
9.7 Pfizer
9.7.1 Pfizer: Ophthalmic Drugs Portfolio
9.7.1.1 Macugen (Valeant/Pfizer)
9.7.2 Pfizer: Sales Forecast 2014-2024
9.7.3 Pfizer: Products in Development
9.7.4 Pfizer: Recent Developments
9.7.4.1 Pfizer Attempts to Acquire AstraZeneca
9.8 Merck
9.8.1 Merck: Ophthalmic Drugs Portfolio
9.8.2 Merck: Sales Forecast 2014-2024
9.8.3 Merck: Products in Development
9.9 Bayer
9.9.1 Bayer: Ophthalmic Drugs Portfolio
9.9.2 Bayer: Sales Forecast 2014-2024
9.10 Senju
9.10.1 Senju: Ophthalmic Drugs Portfolio
9.10.2 Senju: Sales Forecast 2014-2024
9.10.3 Senju: Products in Development
9.10.3.1 Y 39983 (SNJ 1656)
9.10.3.2 Difluprednate (SJE-2079)

10. Ophthalmic Drugs Pipeline Analysis 2014-2024
10.1 The Ophthalmic Drugs Pipeline: Richest in Retinal Disorder Agents
10.2 The Retinal Disorders Pipeline
10.2.1 Will Bevasiranib (RXi Pharmaceuticals) Resume Development?
10.3 Retinal Disorders: Filed or Recently Launched
10.3.1 Compaq Sipp (conbercept, Chengdu Kanghong Pharmaceutical)
10.3.2 Lipidil (fenofibrate, Abbott)
10.3.3 Iluvien (fluocinolone, Alimera)
10.4 Retinal Disorders: Phase 3 Pipeline
10.4.1 Fovista and Zimura (Ophthotech)
10.4.2 MC-1101 (hydralazine, MacuCLEAR)
10.4.3 Tandospirone (serotonin 1A agonist, Alcon)
10.4.4 UF-021 (unoprostone, R-Tech Ueno)
10.5 Retinal Disorders: Phase 2 Pipeline
10.5.1 AKB 9778 (Tie2 activator, Aerpio Therapeutics)
10.5.2 ALG-1001 (Integrin peptide therapy, Allegro/Senju)
10.5.3 AGN150998 and MP0260 (Anti-VEGF DARPins, Allergan)
10.5.4 AGN208397 (beclomethasone, Allergan)
10.5.5 CPC 551 (Colby Pharmaceutical)
10.5.6 Darapladib and GSK933776 (GSK)
10.5.7 ESBA1008 (anti-VEGF mAb, Alcon)
10.5.8 iCo-007 (antisense inhibitor of C-raf kinase mRNA, iCo Therapeutics)
10.5.9 iSONEP (sonepcizumab, Lpath)
10.5.10 Lampalizumab (anti-Factor D Fab, Roche)
10.5.11 LFG316 (anti-C5 mAb, Novartis)
10.5.12 Novadur (Intravitreal brimonidine implant, Allergan)
10.5.13 Optina (danazol, Ampio Pharmaceuticals)
10.5.14 PF-655 (synthetic siRNA, Quark/Pfizer)
10.5.15 Premiplex (protein replacement therapy, Shire)
10.5.16 Renexus (ciliary neurotrophic factor, Neurotech)
10.5.17 Squalamine (anti-angiogenic drug, OHR Pharmaceutical)
10.5.18 Zybrestat (fosbretabulin, Oxigene/Symphony VIDA)
10.6 Retinal Disorders: Phase 1 and Preclinical Pipeline
10.6.1 BDM-E (BioDiem)
10.6.2 NADPH Oxidase Inhibitors (Alimera)
10.6.3 NS2 (aldehyde trap, Aldeyra Therapeutics)
10.6.4 PAN-90806 (topical VEGF inhibitor, PanOptica)
10.6.5 Plasma Kallikrein Inhibitors (KalVista)
10.6.6 QLT091001 (synthetic retinoid, QLT)
10.7 Allergic, Inflammatory and Infective Drugs: Phase 3 Pipeline
10.7.1 EGP-437 (dexamethasone, EyeGate)
10.7.2 IBI-10090 and IBI-20089 (Icon Bioscience)
10.7.3 LE-MPP (loteprednol etabonate, Kala)
10.8 Allergic, Inflammatory and Infective Drugs: Phase 2 Pipeline
10.8.1 CF101 (adenosine A3 receptor agonist, Can-Fite BioPharma and OphthaliX)
10.8.2 FST-100 (povidone-iodine/dexamethasone, ForeSight Biotherapeutics)
10.8.3 NVC-422 (auriclosene, NovaBay)
10.8.4 Sarilumab (Regeneron)
10.8.5 V404 PDS (ForSight VISION4)
10.9 Allergic, Inflammatory and Infective Drugs: Phase 1 and Preclinical Pipeline
10.9.1 Finafloxacin (MerLion Pharmaceuticals/Novartis)
10.10 Glaucoma: Phase 2 and Phase 3 Pipeline
10.10.1 Latanoprostene Bunod (BOL 303259-X, Valeant)
10.10.2 AMA0076 (ROCK inhibitor, Amakem)
10.10.3 Rhopressa (AR-13324; ROCK and NET inhibitor) and Roclatan (PG324; ROCK inhibitor), Aerie Pharmaceuticals
10.11 Glaucoma: Phase 1 and Preclinical Pipeline
10.12 Dry Eye: Phase 3 Pipeline
10.12.1 EBI-005 (IL-1R antagonist, Eleven Biotherapeutics)
10.12.2 Lifitegrast (integrin antagonist, Shire)
10.12.3 MIM-D3 (tyrosine kinase receptor antagonist, Valeant)
10.12.4 SI-614 (modified hyaluronate, Seikagaku)
10.13 Dry Eye: Phase 2 Pipeline
10.13.1 ESBA105 (TNF-alpha antibody, Novartis/Alcon)
10.13.2 Kineret (anakinra: IL-1 receptor antagonist, Amgen/Sobi)
10.14 Other Ophthalmic Drugs Pipeline
10.14.1 Brimonidine for Eye Whitening (Valeant)
10.14.2 GS-101 (aganirsen, Gene Signal)
10.14.3 Omidria (phenylephrine/ketorolac, Omeros)

11. Qualitative Analysis of the Ophthalmic Drugs Market 2014-2024
11.1 SWOT Analysis of the Ophthalmic Drugs Market
11.2 Strengths
11.2.1 Advances in Drug Delivery Technologies
11.2.2 Support for Reimbursement
11.2.3 Strong R&D Pipeline
11.2.3.1 Gene Therapy and RNA Interference Technology
11.2.3.2 New Ophthalmic Therapeutic Applications for Drugs
11.2.3.3 Development of Neuroprotective Anti-Glaucoma Medications
11.2.3.4 Working with Biomarkers
11.3 Weaknesses
11.3.1 Patient Adherence to Treatment
11.3.2 High Treatment Burden
11.3.3 Under-Diagnosis and Under-Treatment
11.4 Opportunities
11.4.1 Increasing Disease Prevalence
11.4.1.1 Ageing of the World Population
11.4.1.2 Increasing Prevalence of Eye Diseases and Diabetes
11.4.1.3 Glaucoma and Retinal Disorders Will Have the Most-Marked Increases in Prevalence
11.4.2 Unmet Clinical Need in Many Disease Areas
11.4.3 Higher Growth in Emerging Markets
11.4.4 Sustained-Release Ocular Implants
11.5 Threats
11.5.1 Generic Competition
11.5.2 Price Regulation
11.5.3 Biosimilars
11.5.4 Increasing R&D Costs
11.6 Porter’s Five Forces Analysis of the Ophthalmic Drugs Market
11.6.1 Rivalry Among Competitors [Medium]
11.6.2 Threat of New Entrants [Low]
11.6.3 Power of Suppliers [Low]
11.6.4 Power of Buyers [Medium]
11.6.5 Threat of Substitutes [Medium]

12. Research Interviews
12.1 Interview with Cathy Yelf, Head of External Relations, Macular Society, Andover, Hampshire, UK
12.1.1 The Work of the Macular Society
12.1.2 Developments in Treating AMD
12.1.3 Lucentis, Eylea and Avastin
12.1.4 Developments in Diagnosis of Eye Conditions
12.1.5 Unmet Needs in AMD
12.1.6 The Future of the Ophthalmic Drugs Market?
12.2 Interview with the Royal National Institute of Blind People (RNIB), London, UK
12.2.1 The Work of RNIB
12.2.2 Developments in Ophthalmology
12.2.3 Unmet Needs in Glaucoma and AMD
12.2.4 The Future of the Ophthalmic Drugs Market?
12.3 Interview with Dr Charles Wykoff, Retina Consultants of Houston, Texas, US
12.3.1 Developments in Ophthalmology
12.3.2 Unmet Needs in Ophthalmology
12.3.3 Regulatory Issues in the US Market
12.3.4 The Future of the Ophthalmic Drugs Market?
12.4 Interview with Professor Manju Subramanian, Associate Professor, Department of Ophthalmology, Boston University School of Medicine, Boston, Massachusetts, US
12.4.1 Developments in Ophthalmology
12.4.2 Unmet Needs in Ophthalmology
12.4.3 Treatments for Glaucoma, AMD and Dry Eye
12.4.4 Lucentis, Eylea and Avastin
12.4.5 Jetrea for Retinal Disorders
12.4.6 The Future of the Ophthalmic Drugs Market?
12.5 Interview with a Spokesperson for Vanda Pharmaceuticals, Washington DC, US
12.5.1 Commercialising Hetlioz
12.5.2 Future Prospects for Vanda
12.6 Interview with Professor David T. Shima, PhD, Institute of Ophthalmology, University College London, UK
12.6.1 On the Role of VEGF in Retinal Disorders
12.6.2 On Candidate Molecule E10030
12.6.3 On Candidate Molecule JSM 6427
12.6.4 On New Sustained Release Formulations
12.6.5 On Delta-Notch Signalling
12.6.6 Potential Clinical Crossovers Between Ophthalmology and Oncology
12.6.7 Commercial and Clinical Possibilities in the Ophthalmology Market
12.6.8 On the Possibilities of Research into the Endothelial Fenestra
12.7 Expert Interview 7: Authority from a Company in the Industry (Views Provided Anonymously)
12.7.1 Key Unmet Needs
12.7.2 Challenges Facing the Ophthalmic Sector
12.7.3 On Current Ophthalmic Treatments and Their Effectiveness
12.7.4 On Opportunities in the Ophthalmic Sector
12.8 Interview with Sean Ainsworth, CEO and Founder of RetroSense Therapeutics, Ann Arbor, Michigan, USA
12.8.1 The Optogenetic Approach to Vision Restoration
12.8.2 Choosing Disease Targets and Delivery Vectors
12.8.3 The Regulatory Picture
12.8.4 Gene Therapies in AMD and Other Ophthalmic Therapeutic Areas
12.8.5 The Next Ten Years for Gene Therapy
12.9 Interview with Philip G. Ralston, Jr., CEO of MacuCLEAR, Plano, Texas, USA
12.9.1 MC 1101: Identifying and Treating Chiou Syndrome
12.9.2 Preventing Dry AMD Progression
12.9.3 Treating the Root Cause of Dry AMD
12.9.4 Phase 3: Endpoints and Prospects for MC 1101
12.10 Interview with Dr Michael Stewart, Associate Professor, Mayo Clinic, Jacksonville, Florida, USA
12.10.1 The Impact of Eylea
12.10.2 The Comparative Dosing Schedules of Eylea and Lucentis
12.10.3 Patient Transitioning to Eylea: Salvage Switching
12.10.4 Avastin after the CATT Study
12.10.5 Prospects for Eylea in Other Indications and Combinations
12.10.6 Future Possibilities in Wet AMD Treatment

13. Conclusions
13.1 Ophthalmic Pharmaceuticals: A Growing Niche Market
13.2 The World Ophthalmic Drugs Market in 2013
13.2.1 Current Leading Ophthalmic Drugs Segments
13.2.2 Leading Ophthalmic Drugs Products
13.2.3 Leading Ophthalmic Drugs Companies
13.2.4 Leading National Markets
13.3 World Ophthalmic Drugs Market Forecast 2014-2024
13.4 Ophthalmic Drugs Late-Stage Pipeline
13.5 The Future of the Ophthalmic Drugs Market?
13.5.1 Increasing Revenue Concentration among Specialist Companies
13.5.2 The Rise of Generics
13.5.3 Small Companies Can Have a Big Impact
13.5.4 What Will Succeed in the Ophthalmic Drugs Market?

List of Tables
Table 1.1 Leading National Ophthalmic Drugs Market Forecast 2014 ($m, AGR%)
Table 2.1 ICD 10 Classification of Visual Impairment, 2010
Table 2.2 Drug Treatments for Glaucoma, 2014
Table 2.3 Drug Treatments for AMD, 2014
Table 2.4 Drug Treatments for Ocular Allergy, 2014
Table 2.5 Drug Treatments for Ocular Inflammatory Disease, 2014
Table 2.6 Selected Drug Treatments for Eye Infections, 2014
Table 2.7 Clinical Trial Phases
Table 2.8 Currency Exchange Rates, 2013
Table 3.1 Top 10 Ophthalmic Drugs: Revenue ($m), 2013
Table 3.2 Top 10 Ophthalmic Drug Manufacturers: Ophthalmic Drugs Revenue ($m), Market Share (%), 2013
Table 3.3 World Ophthalmic Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 3.4 Market Shares (%) of Leading Ophthalmic Drugs Market Segments, 2013, 2018 and 2024
Table 4.1 World Ophthalmic Drugs Market: Revenues ($m) and Market Shares (%) by National Market, 2013
Table 4.2 World Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%) by National Market, 2013-2024
Table 4.2 World Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%) by National Market, 2013-2024 (continued)
Table 4.3 Market Shares (%) of Leading National Ophthalmic Drugs Markets, 2013, 2018 and 2024
Table 4.4 US Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
Table 4.5 Japanese Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
Table 4.6 Chinese Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
Table 4.7 EU5 Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%) by National Market, 2013-2024
Table 4.8 German Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
Table 4.9 French Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
Table 4.10 UK Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
Table 4.11 Italian Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
Table 4.12 Spanish Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
Table 4.13 Brazilian Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
Table 4.14 Russian Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
Table 4.15 Indian Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
Table 4.16 Mexican Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
Table 5.1 Leading Retinal Disorder Drugs: Revenues ($m) and Market Shares (%), 2013
Table 5.2 Retinal Disorder Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Drug, 2013-2024
Table 5.3 Retinal Disorder Drugs Market: Market Shares (%) by Drug, 2013, 2018 and 2024
Table 5.4 Roche/Novartis: Lucentis Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 5.5 Regeneron/Bayer/Santen: Eylea Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 5.6 Roche: Avastin Ophthalmic Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 5.7 Valeant: Visudyne Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 5.8 ThromboGenics/Novartis: Jetrea Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.1 Allergic, Inflammatory and Infective Drugs Submarket Breakdown: Revenue ($m), Market Share (%), 2013
Table 6.2 Leading Allergic, Inflammatory and Infective Drugs: Revenues ($m) and Market Shares (%), 2013
Table 6.3 Allergic, Inflammatory and Infective Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Drug, 2013-2024
Table 6.4 Allergic, Inflammatory and Infective Drugs Market: Market Shares (%) by Drug, 2013, 2018 and 2024
Table 6.5 Novartis/Kyowa Hakko Kirin: Patanol Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.6 Novartis/Kyowa Hakko Kirin: Pataday Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.7 Novartis: Vigamox Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.8 Novartis: TobraDex Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.9 Valeant: Bromday Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.10 Santen: Cravit Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.11 Allergan: Acular Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.12 Akorn: AzaSite Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 7.1 Leading Glaucoma Drugs: Revenues ($m) and Market Shares (%), 2013
Table 7.2 Glaucoma Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Drug, 2013-2024
Table 7.3 Glaucoma Drugs Market: Market Shares (%) by Drug, 2013, 2018 and 2024
Table 7.4 Allergan: Lumigan and Ganfort Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 7.5 Pfizer: Xalatan/Xalacom Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 7.6 Novartis: Travatan/Travatan Z and DuoTrav Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 7.7 Allergan: Alphagan/Alphagan P and Combigan Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 7.8 Merck/Santen: Trusopt Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 7.9 Akorn/Merck/Santen: Cosopt/Cosopt PF Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 7.10 Novartis: Azopt Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 7.11 Santen: Tapros Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 7.12 Akorn: Zioptan Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 8.1 Leading Dry Eye Drugs: Revenues ($m) and Market Shares (%), 2013
Table 8.2 Dry Eye Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Drug, 2013-2024
Table 8.3 Dry Eye Drugs Market: Market Shares (%) by Drug, 2013, 2018 and 2024
Table 8.4 Allergan: Restasis Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 8.5 Allergan: Refresh Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 8.6 Santen: Hyalein Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 8.7 Santen: Diquas Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 8.8 Vanda: Hetlioz Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 9.1 Novartis: Overview, 2014
Table 9.2 Novartis: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 9.3 Allergan: Overview, 2014
Table 9.4 Allergan: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 9.5 Roche: Overview, 2014
Table 9.6 Roche: Lucentis US Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 9.7 Roche: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 9.8 Valeant: Overview, 2014
Table 9.9 Valeant: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 9.10 Regeneron: Overview, 2014
Table 9.11 Regeneron: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 9.12 Santen: Overview, 2014
Table 9.13 Santen: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 9.14 Pfizer: Overview, 2014
Table 9.15 Pfizer: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 9.16 Merck: Overview, 2014
Table 9.17 Bayer: Overview, 2014
Table 9.18 Bayer: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 9.19 Senju: Overview, 2014
Table 9.20 Senju: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 10.1 Ophthalmic Drugs Pipeline by Segment, 2014
Table 10.2 Retinal Disorder Drugs Pipeline: Phase 3 Drugs, 2014
Table 10.3 Retinal Disorder Drugs Pipeline: Phase 2 Drugs, 2014
Table 10.4 Retinal Disorder Drugs Pipeline: Phase 1 and Preclinical Drugs, 2014
Table 10.5 Allergic, Inflammatory and Infective Drugs Pipeline: Phase 3 Drugs, 2014
Table 10.6 Allergic, Inflammatory and Infective Drugs Pipeline: Phase 2 Drugs, 2014
Table 10.7 Allergic, Inflammatory and Infective Drugs Pipeline: Phase 1 and Preclinical Drugs, 2014
Table 10.8 Glaucoma Drugs Pipeline: Phase 2 and Phase 3 Drugs, 2014
Table 10.9 Glaucoma Drugs Pipeline: Phase 1 and Preclinical Drugs, 2014
Table 10.10 Dry Eye Drugs Pipeline: Phase 3 Drugs, 2014
Table 10.11 Dry Eye Drugs Pipeline: Phase 2 Drugs, 2014
Table 10.12 Other Ophthalmic Drugs Pipeline, 2014
Table 11.1 SWOT Analysis of the Ophthalmic Drugs Market, 2014-2024
Table 11.2 World 65+ Population Forecast: Size (m), AGR (%), CAGR (%), 2013-2024
Table 11.3 Global Prevalence Forecast for Ophthalmic Diseases from 2014
Table 13.1 Ophthalmic Drugs Late-Stage Pipeline, 2014

★調査レポート[世界の眼科医薬品市場予測:網膜疾患/アレルギー性炎症/緑内障/眼球乾燥症治療薬] ( Ophthalmic Drugs Market Forecast 2014-2024
Prospects for Leading Companies / VISG409051) 販売に関する免責事項
[世界の眼科医薬品市場予測:網膜疾患/アレルギー性炎症/緑内障/眼球乾燥症治療薬] ( Ophthalmic Drugs Market Forecast 2014-2024
Prospects for Leading Companies / VISG409051) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆